AEON Biopharma (AEON) Stock Price, News & Analysis

Company Overview

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic applications of botulinum toxin. Unlike companies that primarily target aesthetic uses, AEON is developing treatments for neurological and other medical conditions in which botulinum toxin may provide therapeutic benefits.

The company’s lead product candidate is ABP-450, an investigational botulinum neurotoxin type A complex licensed from Daewoong Pharmaceutical. AEON has evaluated ABP-450 in clinical programs targeting conditions including chronic migraine and cervical dystonia, and its broader development strategy may encompass additional therapeutic indications. ABP-450 has not received regulatory approval for these uses.

AEON Biopharma became a publicly traded company through a business combination with Priveterra Acquisition Corp. in 2023 and is headquartered in Irvine, California. The company’s programs are intended for markets in the United States and other international jurisdictions, subject to clinical results and regulatory approvals. Marc Forth serves as the company’s president and chief executive officer.

Key Stats

• Today's Range: $0.29 to $0.32
• 50-Day Range: $0.19 to $0.33
• 52-Week Range: $0.18 to $1.45
• Volume: 1.13 million shs
• Average Volume: 2.93 million shs
• Market Capitalization: $15.46 million
• P/E Ratio: 1.72
• Dividend Yield: N/A
• Price Target: $1.67
• Consensus Rating: Moderate Buy

AEON Biopharma Stock Analysis - MarketRank™

AEON Biopharma scored higher than 91% of companies evaluated by MarketBeat, and ranked 45th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AEON Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

AEON Biopharma has a consensus price target of $1.67, representing about 437.6% upside from its current price of $0.31.

Amount of Analyst Coverage

AEON Biopharma has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for AEON Biopharma are expected to grow in the coming year, from ($0.77) to ($0.69) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AEON Biopharma is 1.72, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.84.

Price to Earnings Ratio vs. Sector

The P/E ratio of AEON Biopharma is 1.72, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.65.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for AEON.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AEON Biopharma does not currently pay a dividend.

Dividend Growth

AEON Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 0.78

News Sentiment

AEON Biopharma has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for AEON Biopharma this week, compared to 1 article on an average week.

Search Interest

17 people have searched for AEON on MarketBeat in the last 30 days. This is an increase of 113% compared to the previous 30 days.

MarketBeat Follows

2 people have added AEON Biopharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.5 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $241,500.00 in company stock, which represents 1.5617% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, AEON Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $241,500.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

9.40% of the stock of AEON Biopharma is held by insiders.

Percentage Held by Institutions

22.78% of the stock of AEON Biopharma is held by institutions.

Company Calendar

• Today: 10/08/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AEON
• Previous Symbol: NASDAQ:AEON
• CIK: 1837607
• Web: www.aeonbiopharma.com
• Phone: (949) 354-6499
• Fax: N/A
• Employees: 8
• Year Founded: 2012

Price Target and Rating

• Average Price Target for AEON Biopharma: $1.67
• High Price Target: $2.00
• Low Price Target: $1.20
• Potential Upside/Downside: +437.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.42)
• Trailing P/E Ratio: 1.72
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$36.63 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -994.63%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.22
• Quick Ratio: 0.22

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($4.12) per share
• Price / Book: -0.08

Miscellaneous

• Outstanding Shares: 49,883,000
• Free Float: 74,373,000
• Market Cap: $15.46 million
• Optionable: Not Optionable
• Beta: 0.69